Updates:
β’ Large account of sales this time gave profitability
β’ Power and fuel cost were in line
β’ Further margins to improve because of new electricity plant at Gujarat
β’ In terms of export and proprietary business, planned strategy is fully getting implemented
β’ Order on hand: At around 350 crores. As this order gets shipped, management feels to get more profitability in terms of margins.
β’ Pharma and chemical sector are looking very very strong
β’ Most of the demand from pharma and chemical is new demand.
Glass Lined front: Margins should remain at same level.
β’ Hyderabad facility has been opened up to cover the backlog.
β’ Price realization is good in the sector and this could done well
β’ Demand from replacement (has 7-8 year cycle)is around 15%, and and new demand is 85%.
β’ Glass lining is locally and metal work is done in India. This saves margin.
β’ Market share is 50-55%, and management expect to increase 10-15% very easily.
β’ Competition from local market: Need for quality is increasing in India. Pricing remain low focus on that of quality. This led to good growth for the co.
β’ Production of Interface is continuance in process. Mainly will start in Germany. Prototype expected to be ready in Dec
Flouro Polymer: Used for in house consumption, however few customer also demand for this product. Company doesn't plan to expand this segment. Main focus would be glass segment.
β’ Germany segment will soon recover from COVID, hence this will also be turned positive EBIDTA soon
Industry aspect: Chemical growth is about if 6%
Pharma growth is about 7% in the quarter.
Company is expecting to see good growth from it expansion of 2.6 Billion $ spend in last 2 year in China and Germany
Order book:
Order this quarter remained better compared to previous quarter and Q2 of Fy 2020.
175cr of order this Q2FY20 which was 170cr in Q1. While this was 100cr in Q1 of FY 2019.
Will remain strong in US and China,
GLE segment:
β’ Order of 800 -900 crore remained same (this was reduced a bit).
β’ Pricing war: Company doens't expect to have margin fight, due to increasing demand of quality. Hence premium from large customer such as SRF, Divis will have low impact on price.
β’ Usage of Debt: Majorly for the acquisition, however due to COVID, working capital need was increase so remaining balance would be conserve for working capital
β’ China which was at negative EBIDTA due to relocation will be turned positive.
Our Conclusion:
β’ Overall the operational front remain positive.
β’ Company is expecting to increase its market share by more 10%.
β’ Quality is now in the focus of Indian business, hence less price war to be expected.
β’ OFS issue will remain to lesson for the company
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
Operation:
β’ Operation were at normal levels and see
β’ Launched new product which is in green market and improved the technology.
β’ Provide power in all areas in significant manner
β’ Witnessed highest manufacturing in power number in last 8 years
New bringing:
β’ Real time electricity market launched in June and witnessed volum
Almost arounde and traded 2,350 MU in this quarter
β’ Green Term-ahead Market (G-TAM), launched on August 21, 2020 saw good response and saw volume of 75.01 MU during the quarter.
-Company facing problems due to Covid
-Granules has achieved the highest numbers in the history of growth story.
-PAT growth of 20% after 2021 with base of 2021.
-ROCE increased due to better utilization of plants.
-Out of approved ANDAs 6 are yet to be launched.
- PAT growth is higher than revenue growth: Due to good product mix, price realization
- Vizag facility is expected to come up next year
- Intentionally delayed launched of some products due to COVID
- Supply chain remain the continuous focus of the company
Updates on Industry:
β’ Ravi season is expected to be good.
β’ Agriculture sector is expected to deliver good growth in the coming months due to good rainfall
β’ Pesticides and Insecticides use was less in the coming quarter.
β’ 3 key products show good growth
β’ Prioritizing cash flow result to increase in cash flow
β’ Main focus remain to bring new and innovative product
New product:
β’ Launched 1 formulation product, and gradual pick up in sales
β’ 2 new crop nutrition product
Data facts:
β’ Opening of economy and there is uplift now from corona
β’ Market shares of company has increase 2.35. Currently at 17.5% market share.
β’ Market share of group and overall business was 24.4%.
β’ Market share product was ULIP at 30%, non Par at 37% and PAr at 33%
Data facts
β’ Policy sold over 4 lacs
β’ New margin business has seen good growth
β’ Main focus now is to control cost.
β’ 48 crores set for provision of Corona, and there is no need for additional provision issue.